Ernst emphasized the strategic transformation of Tivic into a diversified therapeutics company, combining biologic and bioelectronic approaches to address immune dysregulation. This includes ...
Biofrontera Inc. reports a record $37.3M in 2024 revenue, FDA milestones, and strategic growth plans for 2025.
This approval, based on the HELIOS-B Phase 3 clinical trial results, signifies AMVUTTRA as the first and only FDA-approved therapy ... in its impressive 85.62% gross profit margin and healthy ...
TipRanks on MSN11h
scPharmaceuticals’ Earnings Call Highlights Growth and ChallengesScpharmaceuticals (($SCPH)) has held its Q4 earnings call. Read on for the main highlights of the call. The recent earnings call for ...
Q4 2024 revenues were $10.3 million, up 47% from Q4 2023. This was an all-time quarterly record for the Company. Full year 2024 revenues were $32.6 million, up 60% from full year 2023 revenues. This ...
Woburn, Mass., March 21, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company ...
scPharmaceuticals reported Q4 2024 revenue of $12.2 million, FDA approved FUROSCIX for chronic ... 41,000 FUROSCIX doses filled in 2024 Gross-to-net (GTN) discount of 19% and 16% for the fourth ...
Today's Research Daily features new research reports on 16 major stocks, including Philip Morris International Inc. (PM), ...
Reported positive results from the Expanded Access Protocol (NEXT), reinforcing NexoBrid's clinical and real-world benefits across 29 burn centers in the U.S. The study included 239 patients (215 ...
Good day, and welcome to ARS Pharmaceuticals fourth quarter and full year 2024 financial results conference call. (Operator Instructions) As a reminder, this call is being recorded. I would now like ...
Pharmaceuticals generated fourth quarter 2024 net FUROSCIX® revenue of $12.2 million, and full year 2024 revenue of $36.3 million Cash and cash equivalents of $75.7 million as of December 31, 2024 U.S ...
Received European Commission approval for GOHIBIC® (vilobelimab) for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback